Whalesbook
Brand Name Battle in Court
The Delhi High Court has asked Dr. Reddy's Laboratories to pause sales and market expansion for its diabetes drug under the brand name "Olymviq." This request came after Danish drugmaker Novo Nordisk filed a complaint, arguing that "Olymviq" sounds too similar to its well-known drug "Ozempic." Justice Jyoti Singh noted that such phonetic similarities can be critical in the pharmaceutical sector, as they risk confusing consumers and potentially impacting public health. Although Dr. Reddy's also launched its generic semaglutide as "Obeda" at competitive prices, the "Olymviq" name is central to this legal fight. The court suggested Dr. Reddy's consider using its "Obeda" brand instead to avoid confusion. The case is set for another hearing on March 27, with a potential interim injunction still possible.
Generics Spark Price War
Dr. Reddy's was among the first Indian firms to get approval from the Drugs Controller General of India (DCGI) for generic semaglutide. It launched its "Obeda" injection on March 21, 2026, priced at about ₹4,200 per month for 2mg and 4mg doses. This marks a significant drop of roughly 62% compared to Novo Nordisk's highest-dose Ozempic. This aggressive pricing is fueling a broader market shift, with over 40 Indian pharmaceutical companies expected to introduce more than 50 generic semaglutide brands. Prices are predicted to fall between ₹1,300 and ₹8,000 monthly, a sharp contrast to Novo Nordisk's Ozempic, which ranged from ₹8,800 to ₹11,175 per month. The aim is to make GLP-1 therapies more accessible in India, where over 101 million adults live with diabetes and obesity.
Market Race and Global Outlook
India's GLP-1 market, valued at ₹1,446 crore as of February 2026 and expected to surpass $1 billion domestically, is now a key area for market share competition. Leading companies such as Dr. Reddy's, Sun Pharma, Alkem Laboratories, and Natco Pharma are set to capture substantial parts of this fast-growing sector. Dr. Reddy's plans to use its own API and formulation expertise to become a top-five player in India's semaglutide market. Meanwhile, Novo Nordisk, while facing immediate generic competition in India, still holds patent protection in major markets like the US and Europe until 2031-32. The company's P/E ratio of around 10.5-10.8 reflects its strong global standing. However, recent stock price swings show how sensitive the market is to competitive threats and regulatory changes like India's patent expiry. Analysts currently hold a mixed 'Hold' recommendation for Novo Nordisk, with price targets between $43 and $47.
Risks Ahead: Legal Hurdles and Margin Pressure
While the influx of generics means more affordable treatments, several risks are present. For Dr. Reddy's, the continuing trademark dispute over "Olymviq" poses a direct threat. A court injunction could require a rebranding, slowing market entry and raising operational expenses. The Delhi High Court's focus on phonetic similarity as a key factor in pharmaceutical trademark cases suggests stricter enforcement might follow, similar to previous decisions protecting well-known brands like Pfizer's "Zoloft" and Mankind Pharma's "KIND" range.
Moreover, with over 50 generic brands expected, an intense price war is likely. This could significantly reduce profit margins for all companies, including Dr. Reddy's, even with its cost efficiencies. There are also worries about these widely available drugs being misused for lifestyle or cosmetic reasons, potentially leading to regulatory action. How readily doctors prescribe generics over established brands, similar to trends seen in the past insulin market, will also be a crucial factor for Dr. Reddy's and other new entrants. Novo Nordisk, despite facing price pressure in India, still benefits from its strong brand loyalty and patent protection in other key markets. This may allow it to concentrate on higher-margin areas while managing its strategy in India.